FDA’s need for speed could strain small biotechs. Here’s how they can keep up.

<figure><div><img src="https://imgproxy.divecdn.com/TkFYxd1BhyRJFX-UMO6A-WkIyJZppcZoOynOdk9cGr0/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNjYyNzI4MDcuanBn.webp"/></div></figure><p>In a more politically charged environment, getting drugs across the finish line is increasingly complex and uncertain.</p>

Kelly Bilodeau · 2026-04-27

FDA’s need for speed could strain small biotechs. Here’s how they can keep up.

In a more politically charged environment, getting drugs across the finish line is increasingly complex and uncertain.

Source: PharmaVoice